Search

Research by a team at Memorial Sloan Kettering Cancer Center has found important new insights into colorectal cancer in Nigeria that have significant implications for treating the disease in West Africa. This research also expands awareness of how different population groups may require different approaches in the diagnosis and treatment of cancer.

… Wednesday, November 24, 2021 Colorectal cancer is common — and deadly — around the world.   But too often, major population groups are not represented in colorectal cancer research, which focuses mainly on patients in America and Western Europe.   A team of researchers from Memorial Sloan Kettering Cancer

The Patient and Family Advisory Council for Quality (PFACQ) marks five years of ensuring the patient and family perspective is included in everything MSK does.

… Wednesday, January 1, 2020 In 2014, Kate Niehaus, a former patient active in volunteer work for Memorial Sloan Kettering, was approached by Kent Sepkowitz, an infectious disease specialist and Deputy Physician-in-Chief for Quality and Safety, with a proposal to make MSK’s outstanding cancer care even

Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries molecular changes called NPM1 mutations and KMT2A translocations.

… Wednesday, October 29, 2025 On October 24, 2025, the U.S. Food and Drug Administration (FDA)  approved revumenib (Revuforj ® ) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries a molecular change called an NPM1 mutation. In November 2024,

Mutations that drive cancer growth also make a cell more noticeable to the immune system.

… Wednesday, May 11, 2022 Many cancers contain similar genetic “hotspots” — areas of DNA that are likely to be mutated. For example, more than 50% of cancers contain a mutation in a gene called TP53 , often within a narrow DNA range. Researchers know that hotspots can contribute to cancer development and

Get to know Abby Hawk, who got a tattoo of Memorial Sloan Kettering after being treated there for neuroblastoma.

… Friday, September 10, 2021 VIDEO | 00:04 Abby Leaves Her Mark Abby's tattoo shows the latitude and longitude of Memorial Sloan Kettering Cancer Center and the quote "The comeback is always stronger than the setback." Video Details It was a bold request. A high school senior living outside Toledo named

A lifelong smoker overcomes discomfort over what a lung cancer imaging test might reveal. She hopes her experience helps reduce the stigma for others who smoke.

… Thursday, September 19, 2024 Marylou Capes-Platt knew she was at an especially high risk for lung cancer . She had been a heavy smoker for 45 years, starting in her teens and continuing through a decades-long career in the music industry and as a writer and editor. She finally quit in 2007. But the threat

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

… Tuesday, April 30, 2013 Summary Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide. Targeted therapies hold promise for the treatment of many types of cancer. But a common predicament is that in many patients

The treatment that children receive for retinoblastoma can lead to health problems later in life. A new study documents their frequency and extent.

… Monday, February 1, 2016 Summary Retinoblastoma  is a rare childhood cancer that affects the eyes. It is highly treatable but can result in long-term medical consequences. A study conducted by MSK researchers documents the type and frequency of these consequences among survivors. The results will inform

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Thursday, November 2, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Mijin Kim Named A 2023 STAT Wunderkind Mijin Kim, PhD Mijin Kim, PhD , postdoctoral fellow, has been  honored   among the 2023 STAT Wunderkinds. STAT Wunderkinds acknowledges

Membership is a widely accepted mark of excellence in science and considered one of the highest honors a scientist can receive.

… Tuesday, April 28, 2020 Two Sloan Kettering Institute (SKI) researchers have been elected to the National Academy of Sciences (NAS). Scott Keeney, PhD , a molecular biologist, and Christopher Lima, PhD , a structural biologist, join more than a dozen Memorial Sloan Kettering investigators who are already